Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib

Executive Summary

Oncology news and highlights from our US FDA Performance Tracker.

Related Content

Celgene/Bristol: Happy Union Or Runaway Bride?
Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
Daiichi Sankyo Hauls Back Mid-Term Profit Outlook As It Builds Oncology
Lonsurf Hits Phase III OS Target In Gastric Cancer Study
Patient Experience Data May Require Separate Label, Genentech Suggests
Daiichi Presses On With Lead Pexidartinib Trial Despite Liver Toxicity
Keeping Track: Nucala, Genvoya Approved; New Breakthrough Claims For Daiichi Sankyo, Merck Oncologics


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts